About US
Contact us
-
Pfizer, Johnson & Johnson settle high-profile Remicade biosim lawsuit on undisclosed termsFor nearly four years, pharmaceutical heavyweights Johnson & Johnson and Pfizerhave sparred in court over competitive dynamics of the biosimilar industry, demanding the attention of the industry2021/7/28
-
Pfizer, Mylan escape another EpiPen lawsuit after judge scraps pharmacy chain's antitrust complaintsMylan and Pfizer have spent years defending their marketing of thepopular epinephrine injector EpiPen. After a busy couple of monthsin court, the partnershave now wipedtheir hands of another lawsuit.2021/7/28
-
Purdue points to creditor support for bankruptcy plan to escape opioid litigation but will Congress followAs if partaking in the powerful drug it aggressively marketed, being at the forefront of the opioid boom was a dizzying high for Purdue Pharma. But it ultimately proved crippling for the manufacturer2021/7/26
-
Lawmakers press FDA for answers about its plans to restart foreign inspectionsFDA inspections restarted earlier this month in the United States, finally giving the regulator a chance to work through the enormous domestic backlog which accumulated during the coronavirus pandemi2021/7/26
-
Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectationsJohnson & Johnson certainly hasn't had the easiest COVID-19 shotrollout. Still,with sales predictions ranging in the billions and a series of manufacturing improvements ongoing, the company sees2021/7/22
-
With Biovac agreement, Pfizer and BioNTech extend their COVID-19 vaccine manufacturing network to AfricaBypassing patent protections on coronavirus vaccines was one proposal floated in recent months to boost supplies in poor countries.But it’s not a short-term solution and, as some analysts suggest, it2021/7/22
-
Merck's next-gen pneumococcal shot scores FDA nod, setting up high-stakes clash with rival PfizerLet the games begin. Yes, it's asignal for the start of the Olympics. But it's also a call to arms for the next-gen pneumococcal vaccine race. A month after Pfizer gained an approval for its pneumoco2021/7/20
-
AbbVie, Lilly atopic dermatitis hopefuls hit with more delays as FDA's JAK inhibitor holdups carry onWith the FDA’s JAK hesitations wearing on, atopic dermatitis hopefuls fromAbbVie and Eli Lilly will have to keep waiting for a chance to see the market. The companiesseparately said on Friday2021/7/20
-
FDA chief asks for independent investigation into approval of Biogen's Alzheimer's drug AduhelmThe FDA’s reportedly cozy relationship with Biogen ahead of its controversial approval of the drugmaker’s Alzheimer’s disease therapy, Aduhelm, has been at the center of calls for an investigation. N2021/7/13
-
Pfizer to meet with FDA to discuss COVID-19 boosters, but will the U.S. get on board?Amid little consensus on the best strategy to defend against the Delta variant of the coronavirus, Pfizer is making its pitch to the United States government in hopes of speeding abooster shot to Ame2021/7/13